score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical	Clinical evidence		Copy Number	PTEN	Deletion				0.0	0.0		Putatively Actionable	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Putatively Actionable	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001						0				PTEN Deletion	1.0	PROS10448-1115156	PROS10448-1115156-Tumor-SM-5EEBN	
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CDKN2C	Deletion				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with del(1p) resulting in loss of CDKN2C.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122								Putatively Actionable	0.0	Either hemizygous or homozygous CDKN2C loss, identified by FISH, resulted in worse overall survival relative to wild type in a study of 515 multiple myeloma patients.	"Leone, Paola E., et al. ""Deletions of CDKN2C in multiple myeloma: biological and clinical implications."" Clinical Cancer Research 14.19 (2008): 6033-6041."	https://doi.org/10.1158/1078-0432.CCR-08-0347	0				CDKN2C Deletion	0.0	PROS10448-1115156	PROS10448-1115156-Tumor-SM-5EEBN	
Investigate Actionability		Guideline	Clinical trial	Somatic Variant	TP53	Splice Site		0.6491	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	1.0	1.0	0.0	TP53  (Splice Site)		PROS10448-1115156	PROS10448-1115156-Tumor-SM-5EEBN	PROS10448-1115156-Normal-SM-4YS2E
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						PROS10448-1115156		
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R216H	0.04	100.0	0.00022200000000000003	0.0																					0	16.0	0.0	0.012	PDGFB p.R216H (Missense)		PROS10448-1115156	PROS10448-1115156-Tumor-SM-5EEBN	PROS10448-1115156-Normal-SM-4YS2E
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		PROS10448-1115156	PROS10448-1115156-Tumor-SM-5EEBN	
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.53																									0				COSMIC Signature (version 2) 1 (53%)		PROS10448-1115156		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.242																									0				COSMIC Signature (version 2) 6 (24%)		PROS10448-1115156		
